Stock listing
OTC:GNVR Genvor Incorporated Stock
Follow Genvor Incorporated into a list and get an email when it puts out news.
Share price · OTC:GNVR
$0.26 USD -0.12 (-31.7%)
Close on Nov 20, 2026
- Day range
- $0.233 – $0.28 USDNov 20, 2026
- Volume
- 12,500 sharesNov 20, 2026
- Market cap
- $9.47M USDAt the close on Nov 20, 2026 · price × 36.41M shares outstanding
- 52-week range
- $0.014 – $2.00 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $1,409 USDMedian day 100 shares · 32 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:GNVR · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.26 | -0.121 | -31.7% | $0.233 | $0.28 | $0.233 | 12,500 | |
| $0.381 | +0.106 | +38.5% | $0.381 | $0.381 | $0.381 | 100 | |
| $0.275 | -0.025 | -8.4% | $0.49 | $0.49 | $0.27 | 7,905 | |
| $0.30 | -0.45 | -60.0% | $0.329 | $0.74 | $0.30 | 8,385 | |
| $0.75 | 0.00 | 0.0% | $0.75 | $0.75 | $0.75 | 0 | |
| $0.75 | 0.00 | 0.0% | $0.75 | $0.75 | $0.75 | 0 | |
| $0.75 | 0.00 | 0.0% | $0.75 | $0.75 | $0.75 | 0 | |
| $0.75 | 0.00 | 0.0% | $0.75 | $0.75 | $0.75 | 0 | |
| $0.75 | 0.00 | 0.0% | $0.75 | $0.75 | $0.75 | 6 | |
| $0.75 | 0.00 | 0.0% | $0.75 | $0.75 | $0.75 | 0 | |
| $0.75 | 0.00 | 0.0% | $0.75 | $0.75 | $0.75 | 970 | |
| $0.75 | 0.00 | 0.0% | $0.75 | $0.75 | $0.75 | 0 | |
| $0.75 | 0.00 | 0.0% | $0.75 | $0.75 | $0.75 | 0 | |
| $0.75 | 0.00 | 0.0% | $0.65 | $0.75 | $0.65 | 13,732 | |
| $0.75 | 0.00 | 0.0% | $0.75 | $0.75 | $0.75 | 0 | |
| $0.75 | 0.00 | 0.0% | $0.75 | $0.75 | $0.75 | 0 | |
| $0.75 | 0.00 | 0.0% | $0.75 | $0.75 | $0.75 | 100 | |
| $0.75 | 0.00 | 0.0% | $0.75 | $0.75 | $0.75 | 0 | |
| $0.75 | 0.00 | 0.0% | $0.75 | $0.75 | $0.75 | 0 | |
| $0.75 | 0.00 | 0.0% | $0.75 | $0.75 | $0.75 | 0 | |
| $0.75 | 0.00 | 0.0% | $0.75 | $0.75 | $0.75 | 0 | |
| $0.75 | 0.00 | 0.0% | $0.75 | $0.75 | $0.75 | 0 | |
| $0.75 | 0.00 | 0.0% | $0.75 | $0.75 | $0.75 | 0 | |
| $0.75 | +0.135 | +22.0% | $0.64 | $0.75 | $0.64 | 1,662 | |
| $0.615 | -0.068 | -9.9% | $0.615 | $0.615 | $0.615 | 100 | |
| $0.683 | 0.00 | 0.0% | $0.683 | $0.683 | $0.683 | 0 | |
| $0.683 | -0.218 | -24.2% | $0.683 | $0.683 | $0.683 | 100 | |
| $0.90 | 0.00 | 0.0% | $0.90 | $0.90 | $0.90 | 0 | |
| $0.90 | 0.00 | 0.0% | $0.90 | $0.90 | $0.90 | 0 | |
| $0.90 | 0.00 | 0.0% | $0.90 | $0.90 | $0.90 | 0 | |
| $0.90 | +0.06 | +7.1% | $0.72 | $0.90 | $0.72 | 415 | |
| $0.84 | +0.09 | +12.0% | $0.48 | $0.85 | $0.48 | 27,785 | |
| $0.75 | 0.00 | 0.0% | $0.75 | $0.75 | $0.75 | 0 | |
| $0.75 | 0.00 | 0.0% | $0.75 | $0.75 | $0.75 | 0 | |
| $0.75 | -0.013 | -1.7% | $0.75 | $0.75 | $0.75 | 100 | |
| $0.763 | 0.00 | 0.0% | $0.763 | $0.763 | $0.763 | 0 | |
| $0.763 | +0.00 | 0.0% | $0.763 | $0.763 | $0.763 | 100 | |
| $0.763 | 0.00 | 0.0% | $1.00 | $1.00 | $0.763 | 1,115 | |
| $0.763 | -0.237 | -23.7% | $1.00 | $1.00 | $0.763 | 200 | |
| $1.00 | 0.00 | 0.0% | $0.922 | $1.00 | $0.20 | 12,300 | |
| $1.00 | 0.00 | 0.0% | $1.00 | $1.00 | $1.00 | 0 | |
| $1.00 | +0.60 | +149.9% | $1.00 | $1.00 | $1.00 | 101 | |
| $0.40 | -0.083 | -17.1% | $0.60 | $0.60 | $0.40 | 300 | |
| $0.483 | -0.096 | -16.6% | $0.513 | $0.60 | $0.40 | 2,685 | |
| $0.579 | -0.051 | -8.1% | $0.548 | $0.579 | $0.548 | 5,085 | |
| $0.63 | +0.12 | +23.5% | $0.70 | $0.70 | $0.63 | 1,655 | |
| $0.51 | -0.18 | -26.1% | $0.60 | $0.75 | $0.51 | 30,603 | |
| $0.69 | 0.00 | 0.0% | $0.69 | $0.69 | $0.69 | 0 | |
| $0.69 | 0.00 | 0.0% | $0.69 | $0.69 | $0.69 | 0 | |
| $0.69 | 0.00 | 0.0% | $0.69 | $0.69 | $0.69 | 100 | |
| $0.69 | 0.00 | 0.0% | $0.69 | $0.69 | $0.69 | 0 | |
| $0.69 | 0.00 | 0.0% | $0.513 | $0.69 | $0.513 | 1,500 | |
| $0.69 | 0.00 | 0.0% | $0.69 | $0.69 | $0.69 | 3,350 | |
| $0.69 | 0.00 | 0.0% | $0.69 | $0.69 | $0.69 | 100 | |
| $0.69 | 0.00 | 0.0% | $0.70 | $0.70 | $0.69 | 1,400 | |
| $0.69 | 0.00 | 0.0% | $0.69 | $0.69 | $0.69 | 0 | |
| $0.69 | 0.00 | 0.0% | $0.69 | $0.69 | $0.69 | 0 | |
| $0.69 | -0.01 | -1.4% | $0.69 | $0.69 | $0.69 | 100 | |
| $0.70 | 0.00 | 0.0% | $0.68 | $0.70 | $0.68 | 2,800 | |
| $0.70 | -0.04 | -5.4% | $0.70 | $0.70 | $0.70 | 100 | |
| $0.74 | 0.00 | 0.0% | $0.74 | $0.74 | $0.74 | 0 | |
| $0.74 | 0.00 | 0.0% | $0.74 | $0.74 | $0.74 | 0 | |
| $0.74 | +0.43 | +138.5% | $0.40 | $0.74 | $0.40 | 10,050 | |
| $0.31 | 0.00 | 0.0% | $0.31 | $0.31 | $0.31 | 1,000 | |
| $0.31 | -0.24 | -43.6% | $0.40 | $0.40 | $0.31 | 4,500 | |
| $0.55 | 0.00 | 0.0% | $0.55 | $0.55 | $0.55 | 0 | |
| $0.55 | 0.00 | 0.0% | $0.55 | $0.55 | $0.55 | 0 |
- Ticker
- OTC:GNVR
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- OTC
- Currency
- USD
What changed lately
Latest news release · Jul 27, 2026
Genvor’s Antimicrobial Peptides Advance into Sugar Beet Research
Latest deck · March 2026
Investor Presentation (March 2026)
Investor deck · 18 slides
Latest news
Genvor’s Antimicrobial Peptides Advance into Sugar Beet Research
Jul 27, 2026
Closed $0.20 (-63.6%) on Jul 27, 2026
Genvor Appoints Donald Kalkofen as Chief Financial Officer
May 21, 2026
Closed $0.458 (0.0%) on May 21, 2026
Genvor Announces Strategic Memorandum of Understanding with Canlab International(TM) to Advance Peptide Pipeline
Apr 17, 2026
Closed $0.50 (0.0%) on Apr 17, 2026
Genvor Announces Strategic Memorandum of Understanding with Canlab International™ to Advance Commercial Peptide Pipeline
Apr 14, 2026
Closed $0.50 (0.0%) on Apr 14, 2026
Genvor to Present at Centri Capital Conference on April 14
Apr 7, 2026
Closed $0.793 (0.0%) on Apr 7, 2026
Genvor, Inc. Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026
Mar 5, 2026
Closed $0.615 (0.0%) on Mar 5, 2026
Genvor Announces Strategic Expansion into Health and Wellness Market, Leveraging Proprietary AI-Accelerated BioCypher Platform to Develop Consumer Peptide Solutions
Mar 4, 2026
Closed $0.615 (0.0%) on Mar 4, 2026
Genvor’s AGM182 Antifungal Peptide Technology Validated in Peer-Reviewed Publication in PhytoFrontiers™
Feb 11, 2026
Closed $1.25 (0.0%) on Feb 11, 2026
Genvor Appoints Dr. George Stavrides as Executive Vice President, Business Development & Commercialization
Jan 28, 2026
Closed $1.50 (0.0%) on Jan 28, 2026
DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event
Jan 23, 2026
Closed $1.50 (+42.9%) on Jan 23, 2026
Issued by another party
Genvor Incorporated on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 14 in the last 12 months · 26 in all · newest Jul 27, 2026 · oldest 2023
- Decks
- 1 deck · latest March 2026
Valuation
Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $9.27M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- Negative equity
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta vs S&P 500
- 0.44
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Genvor Incorporated · OTC:GNVR | US$9.47M | US$9.27M | n/a | n/a | n/a | n/a | n/a | n/a | 0.44 |
| aTyr Pharma, Inc. · NASDAQ:ATYR | US$9.74M | −US$28.09M | n/a | n/a | n/a | 0.3× | n/a | 0.3× | 2.12 |
| Lisata Therapeutics, Inc. · NASDAQ:LSTA | US$9.71M | −US$273.0M | n/a | −2,730× | n/a | 1.3× | n/a | 0.0× | 0.71 |
| Purple Biotech Ltd. · TASE:PPBT | US$9.70M | US$3.73M | n/a | n/a | n/a | 0.8× | n/a | 0.0× | n/a |
| Jasper Therapeutics, Inc. · NASDAQ:JSPR | US$9.64M | −US$125.6M | n/a | −15.7× | n/a | n/a | n/a | n/a | 2.02 |
| Alzinova AB · OMXSTO:ALZ | US$9.58M | US$8.35M | n/a | 17.0× | n/a | 0.6× | −484.4% | 0.0× | n/a |
| Chemomab Therapeutics Ltd. · NASDAQ:CMMB | US$9.58M | US$4.92M | n/a | n/a | n/a | 2.6× | n/a | 0.0× | 1.04 |
| Poxel SA · EURONEXT:POXEL | US$9.27M | US$73.95M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| TScan Therapeutics, Inc. · NASDAQ:TCRX | US$9.27M | −US$30.80M | n/a | −5.9× | n/a | 0.2× | n/a | 0.9× | 1.66 |
| Rapid Dose Therapeutics Corp · CSE:DOSE | US$9.13M | US$9.12M | n/a | 5.1× | n/a | n/a | −123.1% | n/a | 0.64 |
| CytoMed Therapeutics Limited · NASDAQ:GDTC | US$9.01M | US$8.23M | n/a | 14.7× | n/a | 2.3× | −730.3% | 0.1× | 0.16 |
| Median of the others | US$9.58M | US$4.33M | −0.4× | 0.8× | −484.4% | 0.0× | 1.04 |
Team and board
Officers
| Officer | Role |
|---|---|
| Chad Pawlak | Chief Executive Officer |
| Don Kalkofen | Chief Financial Officer |
| Carly Scaduto | Director, Corporate Communications |
| Genvor Incorporated | Investor Relations |
| George Stavrides | Executive Vice President, Business Development & Commercialization – Agriculture |
| John M. Viglotti | SVP Corporate Services |
| Brianna Fochs | Senior Scientist & Lab Manager |
| Clayton Yates | Co-Founder |
| Jesse Jaynes | Co-Founder |
| Lance Culnane | Director, AI & Machine Learning |
Board
| Director | Role |
|---|---|
| Chad Pawlak | Chief Executive Officer |
| Clayton Yates | Co-Founder |
| Jesse Jaynes | Co-Founder |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (March 2026) | Investor deck | 18 slides | March 2026 |
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | ||||
| Research and development | 455.9K | 240.3K | 0 | 0 | 226.4K | |||
| Selling, general and administrative | 23.8K | 4.87K | 6.00K | |||||
| Operating income | -6.41M | -2.78M | -1.44M | -3.10M | ||||
| Depreciation and amortization | 1.38K | 1.83K | 1.83K | 1.83K | ||||
| EBITDA | -6.41M | -2.78M | -1.44M | -3.10M | ||||
| Interest expense | 59.8K | 17.7K | 43.8K | 102.8K | ||||
| Income before tax | -5.59M | -2.88M | -1.71M | |||||
| Income tax | 0 | |||||||
| Net income | -5.59M | -2.88M | -1.71M | -3.44M | -23.8K | -4.87K | -6.00K | |
| Earnings per share, basic | -0.19 | -0.15 | -0.07 | -0.15 | 0.00 | 0.00 | 0.00 | |
| Earnings per share, diluted | -0.22 | -0.15 | -0.07 | -0.15 | 0.00 | 0.00 | 0.00 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 37.2K | 373 | 44.4K | 296.4K | 0 | 0 | 0 | 0 |
| Current assets | 45.8K | 21.7K | 66.3K | 298.4K | 536.0K | 225.7K | ||
| Property, plant and equipment | 13.9K | 15.7K | 17.6K | 18.9K | 19.4K | |||
| Total assets | 45.8K | 35.6K | 82.1K | 316.0K | 556.9K | 247.1K | 0 | 0 |
| Accounts payable | 516.7K | 571.2K | 33.3K | 7.50K | 0 | |||
| Current liabilities | 1.36M | 1.75M | 1.79M | 1.62M | 2.45M | 2.25M | 17.3K | 15.8K |
| Total debt | 20.0K | 904.5K | 1.32M | 1.14M | ||||
| Total liabilities | 1.36M | 1.75M | 1.79M | 1.71M | 2.79M | 2.74M | ||
| Shareholders' equity | -1.31M | -1.71M | -1.70M | -1.39M | -2.24M | -62.5K | -17.3K | -15.8K |
| Shares outstanding | 30.2M | 20.0M | 19.1M | 38.7M | 26.0M | 24.0M | 20.0M | 20.0M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -555.7K | -975.6K | -871.7K | -663.2K | 0 | 0 | 0 |
| Cash from investing | 0 | 0 | 0 | ||||
| Cash from financing | 592.6K | 931.7K | 619.7K | 899.9K | 0 | 0 | 0 |
| Change in cash | 36.9K | -44.0K | -252.0K | 236.6K | 0 | 0 |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 3, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 26, 2026 | Material contract | SEC |
| 8-K · Current report | Oct 19, 2026 | Material contract | SEC |
| 10-Q · Quarterly report | Aug 14, 2026 | Quarterly report | SEC |
| DEF 14C | Jul 31, 2026 | Meeting notice | SEC |
| PRE 14C | Jul 20, 2026 | Meeting notice | SEC |
| 8-K · Current report | Jun 22, 2026 | Material contract | SEC |
| 3 · Initial statement of ownership | May 26, 2026 | Insider trade | SEC |
| 8-K · Current report | May 21, 2026 | Management or board change | SEC |
All 108 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | May 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 11, 2026 | Financing | SEC |
| 8-K · Current report | Apr 22, 2026 | Material contract | SEC |
| 4 · Change in ownership | Apr 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 14, 2026 | Insider trade | SEC |
| 10-Q/A · Quarterly report, amended | Mar 13, 2026 | Quarterly report | SEC |
| 10-Q · Quarterly report | Feb 12, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 10-K · Annual report | Dec 10, 2025 | Annual report | SEC |
| D | Dec 5, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 5, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 9, 2025 | Insider trade | SEC |
| 10-K/A · Annual report, amended | Sep 9, 2025 | Annual report | SEC |
| 10-Q · Quarterly report | Sep 8, 2025 | Quarterly report | SEC |
| 10-Q · Quarterly report | Sep 8, 2025 | Quarterly report | SEC |
| 8-K · Current report | Sep 4, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Aug 15, 2025 | Quarterly report | SEC |
| NT 10-Q · Late filing notice | Aug 13, 2025 | Explanation request | SEC |
| 10-K · Annual report | Aug 1, 2025 | Annual report | SEC |
| 10-K/A · Annual report, amended | Jul 31, 2025 | Annual report | SEC |
| 4 · Change in ownership | Jul 3, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Jun 30, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | Jun 23, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jun 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2025 | Insider trade | SEC |
| D | Jun 17, 2025 | Other filings | SEC |
| NT 10-Q · Late filing notice | May 12, 2025 | Explanation request | SEC |
| NT 10-Q · Late filing notice | Feb 18, 2025 | Explanation request | SEC |
| NT 10-K · Late filing notice | Jan 31, 2025 | Explanation request | SEC |
| 8-K · Current report | Nov 13, 2024 | Management or board change | SEC |
| 8-K · Current report | Oct 22, 2024 | Management or board change | SEC |
| NT 10-Q · Late filing notice | Aug 15, 2024 | Explanation request | SEC |
| 8-K · Current report | May 31, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | May 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Mar 20, 2024 | Current report | SEC |
| 4 · Change in ownership | Mar 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 18, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Mar 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 15, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Feb 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Jan 23, 2024 | Material contract | SEC |
| 8-K/A · Current report, amended | Jan 18, 2024 | Current report | SEC |
| 10-K · Annual report | Jan 16, 2024 | Annual report | SEC |
| 10-Q/A · Quarterly report, amended | Jan 16, 2024 | Quarterly report | SEC |
| 10-Q/A · Quarterly report, amended | Jan 16, 2024 | Quarterly report | SEC |
| 10-Q/A · Quarterly report, amended | Jan 16, 2024 | Quarterly report | SEC |
| 10-K/A · Annual report, amended | Jan 16, 2024 | Annual report | SEC |
| 8-K · Current report | Jan 16, 2024 | Current report | SEC |
| NT 10-K · Late filing notice | Jan 2, 2024 | Explanation request | SEC |
| 3 · Initial statement of ownership | Nov 14, 2023 | Insider trade | SEC |
| 8-K · Current report | Nov 6, 2023 | Material contract | SEC |
| 8-K · Current report | Oct 10, 2023 | Material contract | SEC |
| 3 · Initial statement of ownership | Sep 13, 2023 | Insider trade | SEC |
| 8-A12G · Registration of a class of shares | Aug 25, 2023 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Jul 6, 2023 | Management or board change | SEC |
| 10-Q · Quarterly report | Apr 24, 2023 | Quarterly report | SEC |
| 10-Q · Quarterly report | Apr 24, 2023 | Quarterly report | SEC |
| 10-K · Annual report | Mar 28, 2023 | Annual report | SEC |
| 10-Q/A · Quarterly report, amended | Sep 1, 2022 | Quarterly report | SEC |
| 10-Q · Quarterly report | Aug 15, 2022 | Quarterly report | SEC |
| 8-K · Current report | Jul 1, 2022 | Meeting outcome | SEC |
| 8-K · Current report | Jun 15, 2022 | Current report | SEC |
| 8-K · Current report | Jun 9, 2022 | Acquisition or disposal | SEC |
| 10-Q · Quarterly report | Apr 27, 2022 | Quarterly report | SEC |
| 10-Q · Quarterly report | Mar 29, 2022 | Quarterly report | SEC |
| 10-K · Annual report | Mar 21, 2022 | Annual report | SEC |
| 424B3 · Prospectus | Nov 12, 2021 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Nov 12, 2021 | Other filings | SEC |
| CORRESP · Letter to the SEC | Nov 1, 2021 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Oct 29, 2021 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Oct 5, 2021 | Other filings | SEC |
| POS AM · Amendment to an effective registration | Sep 9, 2021 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 23, 2021 | Quarterly report | SEC |
| 10-Q · Quarterly report | Aug 5, 2021 | Quarterly report | SEC |
| 10-Q · Quarterly report | Aug 5, 2021 | Quarterly report | SEC |
| 10-K · Annual report | Aug 2, 2021 | Annual report | SEC |
| 10-Q · Quarterly report | Jul 20, 2021 | Quarterly report | SEC |
| 10-Q · Quarterly report | Jul 20, 2021 | Quarterly report | SEC |
| 8-K · Current report | Feb 1, 2021 | Material contract | SEC |
| EFFECT · Notice that a registration is effective | May 14, 2020 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 13, 2020 | Other filings | SEC |
| S-1/A · Registration statement, amended | May 4, 2020 | Offer document | SEC |
| UPLOAD · Letter from the SEC | May 1, 2020 | Other filings | SEC |
| S-1/A · Registration statement, amended | Apr 15, 2020 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Apr 6, 2020 | Other filings | SEC |
| S-1/A · Registration statement, amended | Mar 19, 2020 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Mar 9, 2020 | Other filings | SEC |
| S-1/A · Registration statement, amended | Feb 21, 2020 | Offer document | SEC |
| 8-K/A · Current report, amended | Feb 19, 2020 | Current report | SEC |
| 8-K · Current report | Feb 13, 2020 | Material contract | SEC |
| UPLOAD · Letter from the SEC | Jan 21, 2020 | Other filings | SEC |
| S-1/A · Registration statement, amended | Jan 7, 2020 | Offer document | SEC |
| S-1/A · Registration statement, amended | Jan 2, 2020 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Dec 20, 2019 | Other filings | SEC |
| S-1 · Registration statement | Nov 21, 2019 | Offer document | SEC |
Cap table
Built by 6ix from Genvor Incorporated’s releases · as of Aug 14, 2026
- Common shares
- 36,410,120
- Fully diluted
- 36,410,120
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 36,410,120 | Aug 14, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Aug 14, 2026 | 36,410,120 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Brianna Fochs | Senior Scientist & Lab Manager · Since at least Nov 4, 2026 |
| Carly Scaduto | Director, Corporate Communications · Since at least Jul 27, 2026 |
| Chad Lee Pawlak Sr | Chief Executive Officer, Director · Since at least Jan 17, 2024 |
| Chad Pawlak | Chief Executive Officer · Since at least Apr 16, 2026 |
| Clayton Yates | Co-Founder · Since at least Aug 25, 2023 |
| Donald A Kalkofen | Chief Financial Officer · Since at least May 18, 2026 |
| Don Kalkofen | Chief Financial Officer · Since at least Nov 4, 2026 |
| Genvor Incorporated | Investor Relations · Since at least Apr 17, 2026 |
| George Stavrides | Executive Vice President, Business Development & Commercialization – Agriculture · Since at least Jul 27, 2026 |
| Jessee M Jaynes | Chief Research Officer, Director · Since at least May 8, 2025 |
All 14 people
| Person | Seat |
|---|---|
| Jesse Jaynes | Co-Founder · Since at least Jul 27, 2026 |
| John M. Viglotti | SVP Corporate Services · Since at least Dec 4, 2025 |
| Judith Selene Miller | Chief Business Officer, Director · Aug 25, 2023 – Mar 15, 2024 · Past |
| Lance Culnane | Director, AI & Machine Learning · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about Genvor Incorporated.